CINECA IRIS Institutional Research Information System
IRIS è la soluzione IT che facilita la raccolta e la gestione dei dati relativi alle attività e ai prodotti della ricerca. Fornisce a ricercatori, amministratori e valutatori gli strumenti per monitorare i risultati della ricerca, aumentarne la visibilità e allocare in modo efficace le risorse disponibili.
EnglishThe most recent definition of asthma is that it is a heterogeneous disease, usually characterised by chronic airway inflammation, defined by a history of chronic respiratory symptoms that vary over time, both in frequency and intensity, and associated with variable airflow limitation [1]. Admittedly, asthma is used as an umbrella term, like anaemia, arthritis and cancer. This highlights the importance of taking an individualised approach to a patient's diagnosis and management, using genomics, proteomics, and “humanomics” as emphasised in the GINA guidelines [2]. The vague definition reflects our poor understanding of the underlying mechanisms of the disease, particularly of its more severe expressions. In the guidelines, they are included in steps 4 and 5 of treatment. This might imply that so-called severe asthma is at the extreme of a continuum of severity, something which has never been demonstrated in prospective studies. In contrast to this concept are the observations that: 1) the vast majority of asthmatics (>95%) are treatable [1] and have little if any excessive risk of progression or death [3]; 2) severe asthma improves through intervention on modifiable risk factors [4], particularly because of its undertreatment [1, 5]; and 3) mortality for asthma is not increased nor increasing [6, 7]. Nonetheless, severe asthma is a major health and social burden, even in childhood and adolescence [1, 8].
Scheda prodotto non validato
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo
| Data di pubblicazione: | 2017 | |
| Titolo: | Severe asthma: Phenotyping to endotyping or vice versa? | |
| Autori: | Papi, Alberto; Saetta, Marina; Fabbri, Leonardo | |
| Rivista: | EUROPEAN RESPIRATORY JOURNAL | |
| Keywords: | CLUSTER-ANALYSIS; RESEARCH-PROGRAM; EOSINOPHILIA; POPULATION; DEFINITION; MANAGEMENT; THERAPIES; COHORT; ADULTS | |
| Abstract in inglese: | The most recent definition of asthma is that it is a heterogeneous disease, usually characterised by chronic airway inflammation, defined by a history of chronic respiratory symptoms that vary over time, both in frequency and intensity, and associated with variable airflow limitation [1]. Admittedly, asthma is used as an umbrella term, like anaemia, arthritis and cancer. This highlights the importance of taking an individualised approach to a patient's diagnosis and management, using genomics, proteomics, and “humanomics” as emphasised in the GINA guidelines [2]. The vague definition reflects our poor understanding of the underlying mechanisms of the disease, particularly of its more severe expressions. In the guidelines, they are included in steps 4 and 5 of treatment. This might imply that so-called severe asthma is at the extreme of a continuum of severity, something which has never been demonstrated in prospective studies. In contrast to this concept are the observations that: 1) the vast majority of asthmatics (>95%) are treatable [1] and have little if any excessive risk of progression or death [3]; 2) severe asthma improves through intervention on modifiable risk factors [4], particularly because of its undertreatment [1, 5]; and 3) mortality for asthma is not increased nor increasing [6, 7]. Nonetheless, severe asthma is a major health and social burden, even in childhood and adolescence [1, 8]. | |
| Digital Object Identifier (DOI): | 10.1183/13993003.00053-2017 | |
| Handle: | http://hdl.handle.net/11392/2369476 | |
| Appare nelle tipologie: | 03.1 Articolo su rivista |
File in questo prodotto:
Copyright © 2022